MAGNESIUM MODIFIED ULTRA-STABLE RARE EARTH Y-TYPE MOLECULAR SIEVE AND PREPARATION METHOD THEREFOR
    8.
    发明申请
    MAGNESIUM MODIFIED ULTRA-STABLE RARE EARTH Y-TYPE MOLECULAR SIEVE AND PREPARATION METHOD THEREFOR 有权
    镁改性超稳定稀土Y型分子筛及其制备方法

    公开(公告)号:US20150175432A1

    公开(公告)日:2015-06-25

    申请号:US14365432

    申请日:2012-04-13

    摘要: The present invention provides a magnesium-modified ultra-stable rare earth type Y molecular sieve and the preparation method thereof, which method is carried out by subjecting a NaY molecular sieve as the raw material to a rare earth exchange and a dispersing pre-exchange, then to an ultra-stabilization calcination treatment, and finally to a magnesium modification. The molecular sieve comprises 0.2 to 5% by weight of magnesium oxide, 1 to 20% by weight of rare earth oxide, and not more than 1.2% by weight of sodium oxide, and has a crystallinity of 46 to 63%, and a lattice parameter of 2.454 nm to 2.471 nm. In contrast to the prior art, in the molecular sieve prepared by this method, rare earth ions are located in sodalite cages, which is demonstrated by the fact that no rare earth ion is lost during the reverse exchange process. Moreover, the molecular sieve prepared by such a method has a molecular particle size D(v,0.5) of not more than 3.0 μm and a D(v,0.9) of not more than 20 μm. Such a molecular sieve has both high stability and high selectivity for the target product, while cracking catalysts using the molecular sieve as an active component is characterized by a high heavy-oil-conversion capacity and a high yield of valuable target products.

    摘要翻译: 本发明提供一种镁改性超稳定稀土类Y分子筛及其制备方法,该方法是以NaY分子筛为原料进行稀土交换和分散预交换, 然后进行超稳定化煅烧处理,最后进行镁改性。 分子筛含有0.2〜5重量%的氧化镁,1〜20重量%的稀土氧化物和1.2重量%的氧化钠,结晶度为46〜63%,晶格 参数为2.454 nm至2.471 nm。 与现有技术相反,在通过该方法制备的分子筛中,稀土离子位于钠盐网箱中,这通过在反向交换过程中没有稀土离子损失的事实来证明。 此外,通过这种方法制备的分子筛具有不大于3.0μm的分子粒度D(v,0.5)和不大于20μm的D(v,0.9)。 这种分子筛对于目标产物具有高稳定性和高选择性,而使用分子筛作为活性组分的裂化催化剂的特征在于高重油转化能力和高产率的有价值的目标产物。

    HYPOSIALYLATION DISORDERS
    10.
    发明申请
    HYPOSIALYLATION DISORDERS 有权
    高血压病

    公开(公告)号:US20140271615A1

    公开(公告)日:2014-09-18

    申请号:US14208570

    申请日:2014-03-13

    IPC分类号: G01N33/53

    摘要: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder. In additional embodiments, these methods can be used to determine the lowest effective dosage of the therapeutic agent of use to treat the subject.

    摘要翻译: 公开了用于诊断腰酸症的方法。 还公开了用于确定治疗剂用于治疗受试者中的唾液酸化障碍的有效性的方法。 这些方法包括测量单唾液酸化Thomsen-Friedenreich(ST)抗原的量并测量生物样品中的非唾液酸化Thomsen-Friedenreich抗原(T)的量,例如来自受试者的血清或血浆样品,并测定 T到ST T与单唾液酸化ST的比例约为0.06或更高,可诊断出唾液酸化失调,或表明治疗剂对于治疗唾液酸化失调无效。 在其它实施方案中,T与ST的比值小于约0.06表示治疗剂对于治疗低唾液酸化障碍是有效的,或者受试者不具有低唾液酸化障碍。 在另外的实施方案中,这些方法可用于确定用于治疗受试者的治疗剂的最低有效剂量。